CIK 0001674416
- Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- Operating
- EIN
- 473173478
- Phone
- +1 617-315-4600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-12-06 | Ho Tony W Executive VP, Head of R&D | Shares withheld for taxes | −12,607 | $69.17 | $872K | 52,364 |
| 2021-12-03 | Ho Tony W Executive VP, Head of R&D | Option exercise | +26,667 | 64,971 | ||
| 2021-12-03 | Ho Tony W Executive VP, Head of R&D | Option exercise · Restricted Stock Units | +26,667 | 13,333 | ||
| 2021-10-15 | Ho Tony W Executive VP, Head of R&D | Grant or award · Stock Option (Right to Buy) | +13,800 | 13,800 | ||
| 2021-03-11 | Ho Tony W Executive VP, Head of R&D | Grant or award · Stock Option (Right to Buy) | +23,334 | 23,334 | ||
| 2021-03-11 | Ho Tony W Executive VP, Head of R&D | Grant or award · Restricted Stock Units | +9,000 | 9,000 | ||
| 2021-03-10 | Ho Tony W Executive VP, Head of R&D | Option exercise | +4,583 | 40,445 | ||
| 2021-03-10 | Ho Tony W Executive VP, Head of R&D | Shares withheld for taxes | −2,141 | $124.15 | $266K | 38,304 |
| 2021-03-05 | Ho Tony W Executive VP, Head of R&D | Option exercise | +3,333 | 37,447 | ||
| 2021-03-05 | Ho Tony W Executive VP, Head of R&D | Shares withheld for taxes | −1,585 | $114.65 | $182K | 35,862 |
| 2020-12-21 | Ho Tony W Executive VP, Head of R&D | Option exercise | +23,551 | $16.90 | $398K | 57,515 |
| 2020-12-21 | Ho Tony W Executive VP, Head of R&D | Sale | −1,700 | $148.11 | $252K | 55,815 |
| 2020-12-21 | Ho Tony W Executive VP, Head of R&D | Sale | −900 | $149.18 | $134K | 54,915 |
| 2020-12-21 | Ho Tony W Executive VP, Head of R&D | Sale | −1,600 | $150.16 | $240K | 53,315 |
| 2020-12-21 | Ho Tony W Executive VP, Head of R&D | Sale | −1,100 | $151.58 | $167K | 52,215 |
| 2020-12-21 | Ho Tony W Executive VP, Head of R&D | Sale | −500 | $152.41 | $76K | 51,715 |
| 2020-12-21 | Ho Tony W Executive VP, Head of R&D | Sale | −1,400 | $147.05 | $206K | 50,315 |
| 2020-12-21 | Ho Tony W Executive VP, Head of R&D | Sale | −8,400 | $148.38 | $1.2M | 41,915 |
| 2020-12-21 | Ho Tony W Executive VP, Head of R&D | Sale | −5,000 | $149.73 | $749K | 36,915 |
| 2020-12-21 | Ho Tony W Executive VP, Head of R&D | Sale | −2,951 | $150.61 | $444K | 33,964 |
Page 1 of 3 · 41 trades